Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 305612

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 19

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 19

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Disease
  • Therapeutic
  • Genome
  • Delivery
  • DNA
  • Diabetes Treatment
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 305612

License Grant
Licensor grants a worldwide, exclusive license to make, use, sell, offer to sell, import, export and otherwise exploit the Licensed Subject Matter.
License Property
Licensor is a research company owns or controls certain technology related to ADP Vectors, and desires to conduct further research relating to such ADP Vectors and other matters.  Distinct ADP Vectors means ADP Vectors differing in one or more distinct substantive functions that result in materially different therapeutic effects as to safety and/or efficacy and/or to materially different types of cancer that can be treated.

Licensed Subject Matter means the Collaboration Technologies, the Patent Rights, and, to the extent owned or Controlled by Licensor, any inventions. discoveries and other subject matter covered by or relating to the Patent Rights including, without limitation, the Related Materials.

Licensed Product means a product, composition or material the manufacture, sale or use of which would, but for the license granted herein, directly infringe a Valid Claim in the country for which such product, composition or material is sold, or solely for the purposes of Licensees royalty obligations, a commercial product within the Licensed Subject Matter comprising an ADP Vector.

ADP vector means any composition comprising both DNA or a nucleotide construct, that expresses or promotes the expression of an E3 11.6K protem, or any analog, homologue, variant or derivative of such protein; and a viral vector that is replication competent in at least some cells, alone or in combination with other subject matter. It is understood that an ADP Vector may, in addition, include other subject matter, such as a p53 gene or another gene construct.

The patents include
Replication-Competent Anti-Cancer Vectors;  A Method to Restrict the Rephcatton of Replication-Competent Adenovirus Vectors to Neoplastic Cells;  Recombinant Adcnovirus Vectors that are Replication-Competent in TERT-Expressing Cells;  A Method to Restrict the Replicationcompetent Adenovirus Vectors to Neoplastic Cells.

Field of Use
The purpose is to discover/develop different therapeutic effects as to safety and/or efficacy and/or to materially different types of cancer.

Licensee develops gene therapy products for the treatment of cancer.

IPSCIO Record ID: 244658

License Grant
The Parties have an acquisition agreement.  Upon consummation of the Acquisition, the Parties desire to establish a new cooperative development program intended to discover, develop, and certify for use in humans one or more new pharmaceutical products.

Licensor grants an exclusive, worldwide license under the Ad Interferon-beta Product Licensor Patents and the Ad Interferon-beta Product Technology to develop, research, make, have made, use, have used, sell, offer for sale, import and have sold the Ad Interferon-beta Product in the Cancer Field and the Beta Interferon Field .

For the Manufacturing License,  Licensor will provide a transferable, limited license or subiicense as the case may be under the Licensor Technology and the Licensor Patents to manufacture such Clinical Vectors and Commercial Vectors to the extent necessary to enable Licensee to manufacture quantities of the Clinical Vectors and Commercial Vectors that otherwise would have been supplied by Licensor to Licensee under this Agreement, solely for use and application by Licensee for the uses and applications in the Territory that would be permitted under this Agreement with respect to such Clinical Vectors and Commercial Vectors purchased from Licensor.

Licensor grants a license, with right to grant sublicenses, under the Licensor Technology and the Licensor Patents to research, develop, manufacture, have manufactured, use, import, export, offer to sell or sell Products in the Territory.

Licensor grants  a nonexclusive, worldwide license, with right to sublicense to Contractors permitted under this Agreement,  to the Licensed Technology, other than the Applied Licensor Technology, as designated in the applicable Project Plan and Budget, and under any Licensor Patents, other than the Exhausted Licensed Patents and the Exempted Licensed Patents, as designated in the applicable Project Plan and Budget, which would, but for this license grant, be infringed by Licensees performance of its Development Tasks solely as necessary for performance of Licensees Development Tasks during and in the course of any approved Development Project.

In addition to the other rights granted under this Agreement, Licensor hereby grants an option to acquire a license, with the right to grant sublicenses, to Licensor Technology, that is not otherwise designated as Applied Licensor Technology in the applicable Project Plan and Budget, and under any and all Targeted Patents, that are not designated as Exhausted Licensor Patents or as Exempted Licensor Patents in the applicable Project Plan and Budget.

License Property
The patents include Adenovirus Vectors for Gene Therapy, and, .Method of Reducing an Immune Response to a Recombinant Adenovirus.

AAV Interferon-beta Product means a Product incorporating the Beta Interferon Gene and any AAV Vector as the delivery platform.

AAV Vector means an adeno-associated viral vector useful or potentially useful for the delivery of Genes to human cells.

Ad Interferon-beta Product means the Product incorporating the Beta Interferon Gene and an Ad Vector that is the subject of the Ad Interferon-beta Project.

Ad Vector means an adenoviral vector useful or potentially useful for the delivery of Genes to human cells.

Field of Use
Beta Interferon Field means the treatment or prevention in humans of one or more diseases through the use or application of one or more gene therapy vectors to deliver Genes; such Genes being defined herein as the Beta Interferon Genes.

Cancer Field means the treatment or prevention in humans of one or more cancers through the use or application of AAV Vectors or Ad Vectors.

IPSCIO Record ID: 240474

License Grant
Licensor hereby grants to Licensee a license under the Licensor Patents to the extent necessary to conduct research and development of, and to make, have made, use, offer for sale, sell, have sold and import all Licensed Products throughout the world during the term of this Agreement, which license shall be exclusive (except as to Licensor) in the Shared Territory and shall be exclusive (even as to Licensor) outside of the Shared Territory except that Licensor shall retain such rights in Licensor Patents as shall be necessary to perform its obligations under this Agreement.
License Property
ONYX-015 means any and all formulations of the genetically engineered adenovirus DL1520 described in US Patent Numbers 5,677,178 and 5,846,945 that selectively replicates in and kills cancer cells based on abnormal p53 pathway function and is currently in clinical trials sponsored by Licensor.

Licensor Patent means a Patent that (A) is Controlled by Licensor, and (B) claims any Invention, or the composition of matter, manufacture, and/or use of ONYX-015 or a Licensed Product (or any part or aspect of a Licensed Product), or any technology necessary to research, develop or commercialize Licensed Products, and including Licensors interest in any Joint Patents.

5,801,029 – Cytopathic viruses for therapy and prophylaxis of neoplasia
5,846,945 – Cytopathic viruses for therapy and prophylaxis of neoplasia
5,677,178 – Cytopathic viruses for therapy and prophylaxis of neoplasia

Gene Product means the adenovirus product selected by Licensee. The parties collaborate to identify a Gene Product based on incorporation of a specific gene, selected by Licensee and encoding a specific member of one of three classes of proteins, into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of expressing in cancer cells a particular protein with useful anti-cancer activity.

Independent Product shall have the meaning If, Licensee either (A) is not deemed to be diligent(b) or (c) or terminates Development as to a Licensed Product, in each case after the filing of an IND therefor and prior to the End of Phase II Clinical Trials for such Licensed Product, or (B) fails to fulfill its obligations with respect to diligent Development of a Licensed Product after the End of Phase II Clinical Trials.

Pro-Drug Product means the adenovirus product selected by Licensee to identify a Pro-Drug Product based on incorporation of a gene for a prodrug activating enzyme into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of activating a prodrug into a specific active drug form.

Licensed Product means Local/Regional ONYX-015, Systemic ONYX-015, the Pro-Drug Product (upon selection of the Selected Drug System pursuant to this agreement(b)) or the Gene Product (upon selection of the Selected Gene pursuant to this agreement(c)), but excluding those of the foregoing that become Independent Products unless and until such time as Licensee exercises its buy-back rights under this agreement or that become Terminated Products.

Local/Regional ONYX-015 means the unmodified ONYX-015 currently in clinical trials sponsored by Licensor, and including any formulation thereof, such as, but without limitation, lyophilized formulations, mouthwash formulations, and formulations that stabilize ONYX-015 for storage at refrigerated or room temperature, but excluding modified formulations that comprise Systemic ONYX-015.

Field of Use
ONYX-015 is a novel therapy that uses a genetically modified virus to kill cancer cells.  Onyx-015 is an adenovirus that has been genetically altered so that it only replicates in cells that are lacking a gene called P-53, which is a known tumor suppressor. Because cancer cells lack the gene, the virus multiplies in them and ultimately destroys them. It has no effect on normal cells.

IPSCIO Record ID: 248957

License Grant
Licensor grants to Licensee an exclusive (except as to Licensor) license under the Licensor Patents to the extent necessary to conduct research and development of, and to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Shared Territory during the term of this Agreement.

Licensor hereby grants Licensee a paid-up non-exclusive license to use Licensor Know-How in the Shared Territory to the extent necessary to research, develop and Commercialize the Licensed Products during the Research Term and while Licensee is co-promoting the applicable Licensed Product in the Shared Territory.

License Property
ONYX-015 means any and all formulations of the genetically engineered adenovirus DL1520 described in US Patent Numbers 5,677,178 and 5,846,945 that selectively replicates in and kills cancer cells based on abnormal p53 pathway function and is currently in clinical trials sponsored by Licensee.

5,677,178 – Cytopathic viruses for therapy and prophylaxis of neoplasia
5,846,945 – Cytopathic viruses for therapy and prophylaxis of neoplasia

Neoplasia is the formation or presence of a new, abnormal growth of tissue.

Gene Product means the adenovirus product selected by Licensor.  The parties collaborate to identify a Gene Product based on incorporation of a specific gene, selected by Licensor and encoding a specific member of one of three classes of proteins, into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of expressing in cancer cells a particular protein with useful anti-cancer activity.

Independent Product shall have the meaning If, Licensor either (A) is not deemed to be diligent(b) or (c) or terminates Development as to a Licensed Product, in each case after the filing of an IND therefor and prior to the End of Phase II Clinical Trials for such Licensed Product, or (B) fails to fulfill its obligations with respect to diligent Development of a Licensed Product after the End of Phase II Clinical Trials.

Pro-Drug Product means the adenovirus product selected by Licensor to identify a Pro-Drug Product based on incorporation of a gene for a prodrug activating enzyme into ONYX-015, or another adenovirus agreed to by the Parties that selectively replicates in and kills cancer cells based on abnormal p53 pathway function, for the purpose of activating a prodrug into a specific active drug form.

Licensed Product means Local/Regional ONYX-015, Systemic ONYX-015, the Pro-Drug Product (upon selection of the Selected Drug System pursuant to this agreement(b)) or the Gene Product (upon selection of the Selected Gene pursuant to this agreement(c)), but excluding those of the foregoing that become Independent Products unless and until such time as Licensor exercises its buy-back rights under this agreement or that become Terminated Products.

Local/Regional ONYX-015 means the unmodified ONYX-015 currently in clinical trials sponsored by Licensee, and including any formulation thereof, such as, but without limitation, lyophilized formulations, mouthwash formulations, and formulations that stabilize ONYX-015 for storage at refrigerated or room temperature, but excluding modified formulations that comprise Systemic ONYX-015.

Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 202789

License Grant
Pursuant to prior agreements between Licensor and a University, and Licensor and a third party for the technology development, the Licensor has the right to sublicense the technology to the Licensee.  Licensor grants to the Licensee the identical terms that it receives, and this amendment identifies the royalty rate and patent application information and expands the field of use to exclusive and include sales.

In the original sublicense agreement Sublicensor grants to Sublicensee a non-exclusive, perpetual, non-cancellable sublicense to manufacture, have manufactured, use and research Licensed Products and to otherwise exploit Licensed Technology, but only for research purposes and not for commercial use, in the Field throughout the Territory, including the right to grant further sublicenses, it being intended that the sublicense herein granted covers all rights of Sublicensor in the Licensed Subject Matter in the Field and in the Territory.

The original License the University grants to this agreement Licensor, an exclusive license to manufacture, have manufactured, use and/or sell the Licensed Produces, to practice any method, process or procedure and to otherwise exploit the Licensed Subject Matter, within the Licensed Territory for use within the field.

License Property
The technology is U.S. Provisional Patent Application No. 61/512,244 TUSC2 Therapies for Cancer; Methods of predicting a response to a TUSC2 (also known as FUS1) therapy, improved constructs of TUSC2 preparations including use of a “mini-CMV promoter” and TUSC2 therapy combined with EGFR TKI drugs,  UTSC.P1085US.

The original agreement license property is
Patent and technology rights for U.S. and Foreign Patent Application entitled
•Methods and Compositions for the Selective Inhibition of Gene Expression
•Australia Serial No. 15704/92; Canada Serial No. 2108144; European Serial No. 92908663-5; and
•Methods and Compositions for Retroviral Vector Mediated Transduction, Continuation-in-part U.S. Serial No. 960513; and
•Methods and Compositions for the Selective Inhibition of Gene Expression, Continuation-in-part U.S. Serial No. 987235; and
•Recombinant p53 Adenovirus Methods and Compositions, Continuation-in-part U.S. Serial No. 145826;
•An Adenovirus Supervector System, Continuation-in-part patent has not been filed yet; and
•Recombinant p53 Adenovirus Methods and Compositions, U.S. Serial No. 224232; and
•Methods and Compositions Comprising DNA Damaging Agents and p53, Continuation-in-part patent has not been filed yet; and
•Use of Lectins for the Delivery and Translocation of Genetic Material Across Cell Membranes, patent has not filed yet; and
•Reconstruction of a-FAS/APO-1 Mediated-Apoptosis in Human Cancer Cells by Adenovirus-Mediated transduction of the Wildtype p53 Gene, patent has not filed yet

Field of Use
This agreement is for the drug industry relating to cancer therapy.

Cancer can spread when cells’ natural cancer suppression functions are impaired. The tumor suppressor gene called Tumor Suppressor Candidate 2, or TUSC2 (which was formerly known as FUS1) has been shown to affect both cell proliferation and apoptosis. TUSC2 is a pan-kinase inhibitor, which means that it has the ability to inhibit multiple kinase receptors, such as EGFR and platelet-derived growth factor receptor, or PDGFR. TUSC2 is frequently inactivated early in the development of lung cancer, and loss of TUSC2 expression in NSCLC is associated with significantly worse overall survival compared to patients with normal TUSC2 expression. Many types of cancer cells, including approximately 85% of NSCLC cells, lack expression of TUSC2.

IPSCIO Record ID: 352696

License Grant
Licensor is willing to grant to Licensee, a non-exclusive research license to conduct certain research to identify and select Specified Vectors for specified indications and an option to obtain a non-exclusive license to research, develop, and commercialize Licensed Products for specified indications.

For the Research License Grant, including the Retained Rights, during the Research Term, Licensor grants to Licensee a non-exclusive, non-transferable, worldwide license under the Licensed Research Patents to make, have made, and use any and all AAV Materials in the Research Field, including, for the avoidance of doubt, the right to conduct research and pre-clinical development, solely for purposes of identifying and selecting Specified Vector(s) for use in the Commercial Field upon exercise of a Commercial Option.  For the avoidance of doubt, the foregoing license does not include the right to sell, offer for sale, or import any AAV Materials.

For the Commercial License Option. Licensor grants to Licensee the option, exercisable at Licensees sole discretion, to obtain a non-exclusive worldwide license with respect to each of the Disease Indications and a single Specified Vector for such Disease Indication.

For the License Grant Upon Exercise, if Licensee exercises the Commercial Option for a
particular Disease Indication, effective upon both Licensors receipt of the notice and in the case of a Secondary Disease Indication, the fee described for such Secondary Disease Indication, including the Retained Rights. Licensor grants, to Licensee non-exclusive, sublicensable, non-transferable, worldwide license under the applicable Licensed Commercial Patents to make. have made, use, import, sell, and offer for sale Licensed Products using the Specified Vector solely in the Commercial Field for such Disease Indication, including, for the avoidance of doubt, the right to conduct research and development.

License Property
Licensor has rights under certain patents pertaining to various recombinant adeno-associated virus vectors.

AAVrh10 means the recombinant adeno-associated virus serotype rh10 vector with the specified sequence set forth in GenBank {protein id AAO88201) and (b) any recombinant
adeno-associated virus derivatives of such serotype rh10 vector that arc covered by the claims of the Licensed Research Patents.

Disease lndications means one or more of the following indications Friedreichs Ataxia that is treated or prevented by administration of the applicable recombinant adeno-associated virus serotype vector directly to the central nervous system, brain and spinal cord, Friedreichs Ataxia CNS, Friedreichs Ataxia that is treated or prevented by administration of the applicable recombinant adeno-associated virus serotype vector by any route except administration directly to the central nervous system, brain and spinal cord, Friedrcichs Ataxia Systemic, Huntingtons Disease, and  Amyotrophic Lateral Sclerosis.

Licensed Product means any product using the applicable Specified Vector capsid protein that is made, made for, used, sold, offered for sale, or imported by Licensee, its Affiliates, and any of its or their Sublicensees, the manufacture, use, sale. offer for sale, or import of which product, in the absence of the license granted pursuant to this Agreement, would infringe or is covered by at least one Valid Claim of the Licensed Commercial Patents in the country of manufacture, use, sale, offer for sale, or import; or any service sold by Licensee.

Field of Use
The license agreement for use of Licensor’s proprietary NAV® vectors for the development and commercialization of gene therapies to treat Amyotrophic Lateral Sclerosis (ALS), Friedreich’s ataxia (FA) and Huntington’s disease (HD).

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive, fatal neurodegenerative disease that leads to muscle weakness, loss of mobility, impaired speech, and difficulty breathing and swallowing.

Friedreich's ataxia (FA) is the most common hereditary ataxia, with approximately 8,000 patients living with the disease in the United States and Europe.  FA patients have a genetic mutation in the FXN gene, which limits the production of the protein frataxin, causing a variety of debilitating symptoms and complications, loss of coordination and balance, muscle weakness, impaired vision, hearing and speech, scoliosis, diabetes, and cardiomyopathy.

Huntington’s disease (HD) is an inherited neurodegenerative disorder where symptoms typically become noticeable between 30 and 50 years of age.  HD is caused by a genetic mutation in the huntingtin gene, which leads to the production of a mutated huntingtin protein, resulting in symptoms such as chorea, rigidity, abnormal posturing, cognitive impairment and psychiatric symptoms, and difficulty with speech and swallowing.

IPSCIO Record ID: 294014

License Grant
Licensor, a medical research centers, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
The patents and patent applications relate to Modified Adena-Associated Virus Vector Capable of Expression from a Novel Promoter.

Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.

Field of Use
The field of use is the development of compositions and methods utilizing Adeno-Associated Viral Vectors embodied in the Licensed Patent Rights which are useful in the treatment and prophylaxis of human and animal diseases, and does not include compositions and methods for the treatment and prophylaxis of cystic fibrosis.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.

IPSCIO Record ID: 344585

License Grant
Licensor of England grants a worldwide non-exclusive license to use the System, the Cell Lines, the Materials, and the Intellectual Property to develop, manufacture, market and sell Product.
License Property
Licensor is the proprietor of a system for gene expression utilizing glutamine synthetase.

The patents are titled
Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide employing same;
Recombinant DNA Sequences, Vectors containing them and Method for the use thereof;
Recombinant DNA Product and Processes using it , and,
Recombinant DNA Methods, Vectors and Host Cells.

Product means DNA/histone directed antibody of human or chimeric origin, in combination with radio isotope or another component, of which antibody Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials.

System means the glutamine synthetase gene expression system of which Licensor is the proprietor, as the same is described in the Intellectual Property.

Field of Use
The Licensee has been engaged in the development of drugs and related therapies for the treatment of people with cancer.

IPSCIO Record ID: 369334

License Grant
Licensor of England grants a world-wide non-exclusive license under the Intellectual Property to exploit the System make, have made, use, develop, manufacture, market, sell, have sold, offer for sale, distribute, import, and export Product in the Territory.
License Property
The Product means a humanized monoclonal antibody known as Sphingomabâ„¢, which targets sphingosine-1-phosphate (S1P), or an S1P-binding fragment thereof, of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System.

The System means Licensors glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination with each other.

Field of Use
Licensee has announced the humanization of its Sphingomabâ„¢ monoclonal antibody against sphingosine-1-phosphate (S1P). S1P is an important bioactive lipid that has been well validated as a cancer drug target.

IPSCIO Record ID: 372469

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
—  exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and;
—  non exclusive for Products containing non-human lentivirus vector.
License Property
Licensor has identified and patented a specific nucleotide sequence having a triplex structure, referred to as DNA flap, covered by patents and patent applications.

Ex vivo gene therapy shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene and transplanted back into patient.

Field of Use
Field shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALO) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to betathalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease; for Parkinsons Disease and eye diseases (including but not limited to AMD and Stargardt disease)].  The Field includes in vivo as well as ex vivo gene therapy.

IPSCIO Record ID: 291138

License Grant
University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 1 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee.

Group 2 License Grant. University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 2 Patents in all fields of use. Such right and license shall be non-exclusive to Licensee in the LSD Field.  Subject to this Agreement, such right and license shall be exclusive to Licensee outside the LSD Field.

University hereby grants to Licensee and the Covered Affiliates for the term of this Agreement the worldwide right and license, with the right to grant sublicenses, to develop, have developed, make, have made, use, have used, import, have imported, sell, offer for sale and have sold University Licensed Products under the Group 3 Patents in in all fields of use.   Subject to this Agreement, such rights and license shall be exclusive to Licensee.

License Property
Group 1 Patents means the following patents
US 6,475,769 – Methods and cell line useful for production of recombinant adeno-associated viruses
US 7,238,526 – Methods and cell line useful for production of recombinant adeno-associated viruses

Group 2 Patents means the following patents
US 6,759,237 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US 7,186,552 – Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same

Group 3 Patents means
US 7,056,502 – Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids

University Licensed Product(s) means products that in the absence of this Agreement would, where and when made, used, sold, or imported, infringe at least one issued claim or pending claim of University Patent Rights; and products that are made using a process or machine that in the absence of this Agreement would, where and when used, infringe at least one issued claim or pending claim of University Patent Rights. All University Licensed Products intended to deliver the same Gene shall be considered a single University Licensed Product for purposes of this Agreement.

University Patent Rights means those patents and patent applications listed in this Agreement and all foreign counterparts thereof, as well as continuation, continuation-in-part, provided that such continuation-in-part relates directly to existing patents or patent applications and not to any new matter, divisional and re-issue applications
thereof, together with any and all patents issuing thereupon or upon any foreign counterparts thereof; provided, however, that Licensee acknowledge that the invention relating to non-invasive delivery of transgenes into the bloodstream, which is disclosed in Example 6 of International Patent Application No. PCT/USO1/13000 (M2304PCT), and in a US CIP application No. 09/955,444 (N2605), was made at University following termination of the research under the Sponsored Research Agreement.  Licensee hereby acknowledge that they have no rights in this invention relating to non-invasive delivery of transgenes into the bloodstream, as defined in these applications and divisionals, continuations, re-examinations, re-issues, and any foreign counterparts thereof, and any patents issuing therefrom. Licensee agree that they will not make or pursue any claims that this invention as so defined is or should have been part of the University Patent Rights.

Gene means any nucleotide sequence that is capable of encoding, or of causing or modulating the expression of, a proteiin, protein fragment, or other genetic element.  For the purposes hereof, a Gene having 90% homology to that of another Gene, and which expresses essentially the same protein for at least one biological function, shall be considered the same Gene as such other Gene.

LSD Field means the prevention, treatment, or cure of lysosomal storage diseases whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).

Cancer Field means the prevention, treatment or cure of malignancies whether by in vivo or ex vivo means together with preparation, research, development, and attempts to do the foregoing).

TNFr/Inflammatory Field means the prevention, treatment, or cure of any disease or diseases in whole or in part through use or delivery of the TNFr Gene or any other Gene acting in the Inflammatory Pathway, whether by in vivo or ex vivo means (together with preparation, research, development, and attempts to do the foregoing).

Field of Use
This agreement pertains to the drug industry relating to Gene Therapy.

IPSCIO Record ID: 291169

License Grant
Licensor hereby grants to Japanese Licensee, in the Field and within the Territory
(a) a non-exclusive right and license, with the right to sublicense, under the Licensor Background Technology to make, have made, use, sell and import Program Antibodies;
(b) a non-exclusive right and license, with the right to sublicense, under any Patent Rights and Know-How Controlled by Licensor Covering any control antibodies provided by Licensor for the sole purpose of using such control antibodies to evaluate the Program Antibodies; and
(c) an exclusive right and license, with the right to sublicense, under any Program Patent Rights or other Patent Rights and Know-How Controlled by Licensor Covering each antibody-producing cell line created by Licensor that expresses a Program Antibody provided by Licensor, for the sole purpose of using such cell line to produce the applicable Program Antibody.
License Property
Licensor Background Technology means any and all Know-How and Patent Rights owned by Licensor as of the Effective Date or that come to be Controlled by Licensor during the Program Term (other than the Program Technology) and, in particular, any such Patent Rights and Know-How Covering any Collaboration Target, Program Antibody or Collaboration Product, that are necessary for (a) research related to Collaboration Target(s) or (b) Research and Development, Manufacture or commercialization of Program Antibody(ies) or Collaboration Product(s). For the avoidance of doubt, the Parties acknowledge that, to the extent any Licensor Background Technology is covered by a license or other agreement with a Third Party, such Licensor Background Technology shall, for all purposes of this Agreement, be subject to the limitations, restrictions and financial obligations established in such Third Party license or agreement, with Licensee being responsible for payment of the portion of the financial obligations related to this Agreement arising as a result of the Collaboration. Licensor Background Technology excludes the Human Engineeringâ„¢ Technology.

Antibody means any immunoglobulin molecule whether in monospecific or any other form and shall include, without limitation, immunoglobulin fragments, such as Fv, Fab, F(ab’) and single-chain antibodies.

Program Antibody means an Antibody Product that (a) is identified or discovered by Licensor in the course of the Collaboration, or (b) the Parties agree to acquire from a Third Party, and, in the case of clauses (a) and (b), selectively binds to and acts through a Collaboration Target; provided, however, that in no event shall an Antibody Product that is subject to one or more Pre-existing Obligations become a Program Antibody unless such designation is affirmatively agreed to by the Joint Steering Committee after disclosure of the nature of such Pre-existing Obligation(s) by the applicable Party, such agreement not to be unreasonably withheld or delayed.

Antibody Product means any composition of matter or article of manufacture consisting essentially of an Antibody (a) alone or (b) integrally associated with a composition of matter or article of manufacture (including without limitation conjugates bound to a toxin, label or other moiety) providing therapeutic, half-life, safety or other advantages to the Antibody.

Program Patent Rights means any Patent Rights Controlled by a Party or jointly by the Parties that Cover any Program Technology or Program Materials.

Patent Rights means all patents and patent applications existing as of the Effective Date and all patent applications thereafter filed and patents thereafter issued, including, without limitation, any continuations, continuations-in-part, divisionals, provisionals or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.

Field of Use
Field means any and all uses except, until the expiration or termination of the Chiron Exclusivity Period, the diagnosis, prevention, control or treatment of Cancer.

IPSCIO Record ID: 289753

License Grant
Licensor hereby grants to Licensee, an exclusive, perpetual, worldwide, sublicenseable, royalty-bearing license, under the Licensed IP to conduct Development and Discovery activities with the Transferred Compounds and Licensor Retinoid KnowHow, to make, have made, use, import and offer for sale, and sell Products in the Licensee Field, and to perform Licensees obligations under this Agreement. By way of clarification and without limitation, notwithstanding any provisions of this Agreement, Licensor retains all right, title and interest in and to the Licensed IP for applications in the Licensor Field.
License Property
Product shall mean any pharmaceutical formulation, preparation or product which is covered by, or is made by a process covered by, any Valid Claim, or which utilizes the Licensor Retinoid KnowHow or incorporates as an active pharmaceutical ingredient a Transferred Compound.

Licensed IP shall mean all Patents (and applications) listed and Licensor Retinoid Know-How and Sublicensed lP.
5,906,920 – Methods for the detection of ligands for retinoid X receptors
5,707,800 – Retinoic acid response elements and assays employing same
5,602,009 – Dominant negative chimeras of the steroid/thyroid superfamily of receptors

Transferred Compound shall mean any chemical entity that is (i) included in the Licesor Retinoid Library, (ii) of the same class as any of the foregoing, which in each case has been discovered, developed, synthesized or subject to Licensed TP patent rights filed as of the Effective Date or is a derivative or improvement thereof (but not including any such derivative or improvement that is separately patentable and is outside the scope of generic claims of Licensed TP patents filed as of the Effective Date) or (iii) covered by a Valid Claim. Notwithstanding the foregoing, Transferred Compound shall exclude Tazarotene, the corresponding acid (Tazarotenic acid), and esters and salts of Tazarotenic acid.

Licensor Retinoid Know-How shall mean all technical knowledge, engineering knowledge, unpatentable inventions, trade secrets, manufacturing secrets, secret processes, formulae, manufacturing procedures, methods, data and current and accumulated experience of the Work Force as the result of their scientific research, practical experience and otherwise in the development of the Licensor Retinoid Library and Licensor Retinoid Assays within the Licensee Field that are owned or controlled by Licensor as of the Effective Date relating to the Discovery, Development, composition of matter, formulation, use or manufacture of Transferred Compounds for application in the Licensee Field and retained within the minds of the Work Force.

Licensor Retinoid Library shall mean those items specifically listed. Notwithstanding the foregoing, Licensor and Licensee acknowledge that the Licensor Retinoid Library set forth only constitutes a partial list of constituent compounds as of the Effective Date and that a complete list of such compounds shall be reasonably agreed upon by Licensor and Licensee no later than thirty (30) days following the Effective Date. Upon the final determination of such compounds, the list shall be automatically updated to reflect the inclusion of any additional compounds, which will be deemed to have been included as of the Effective Date.

Licensor Retinoid Assays shall mean (i) Nuclear Hormone Receptor/Kinase Interaction Assay (an assay for identifying compounds that modulate the activity of nuclear hormone receptors and their interacting kinases, as generally described in U.S. Patent Application Number 20030077664); (ii) Bcatenin Assay (an assay for identification of anti-cancer retinoid compounds, as generally described in PCT International Patent Application Number WO 2004000231 ); and (iii) Co-transfection Assay (an assay for identifying compounds that activate retinoic acid receptors and retinoid X receptors, as generally described in U.S. Patent Number 5,071,773).
5,071,773 – Hormone receptor-related bioassays

Advanced Compound shall mean any of the compounds referred to by the following designations AGN 200354; AGN 194204; AGN 195203; AGN 201227; and AGN 201797.

Field of Use
The indications for the lead compounds are acute myeloid leukemia, solid cancers (lung and breast) and chemotherapy-induced neutropenia (low white cell count).  Neutropenia is the presence of abnormally few neutrophils in the blood, leading to increased susceptibility to infection. It is an undesirable side effect of some cancer treatments.  It can be caused by diseases that damage the bone marrow, infections, or certain medications.

Licensee Field shall mean any and all applications and uses of Transferred Compounds outside of the Licensor Field, including without limitation all dermatological, neurological and neurodegenerative applications.

Licensor Field shall mean any use of Transferred Compounds for ophthalmological applications. To the extent provided herein, Licensors rights hereunder may add to the Licesor Field under certain circumstances, and specifically may include, subject to Section 3.4(A), the right to use Transferred Compounds for Neurological Applications and may include, subject to Section 3.4(B), the right to use Transferred Compounds for dermatological applications.

IPSCIO Record ID: 362432

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patent Rights and Licensed Technology and Licensors interest in any Improvements, subject at all times to the restrictions and obligations under a Stanford Agreement with respect to the Stanford IP, to research, develop, test, obtain Regulatory Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products, including, without limitation, any Dimerizer included or utilized therein, in the Territory, for any and all uses within the Licensed Field during the Term, and to make, have made, use, import and export, in each case solely for research purposes, including pre-clinical IND-enabling toxicology and other pre-clinical studies, but not to conduct clinical trials with respect to or to obtain Regulatory Approval for, sell or commercialize, Licensed Products, including, without limitation, any Dimerizer included or utilized therein, for any indication other than the Primary Indications until the end of the Expansion Period and, if Licensee elects to add Additional Indications to the Licensed Field during the Expansion Period, for any indication other than the Primary Indications and the Additional Indications until the end of the Non-Cancer Expansion Period.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is the owner of or otherwise controls certain proprietary Licensed Patent Rights and Licensed Technology.

Licensors Dimerizer shall mean the compound known as xx1903, all analogs and derivatives of xx1903 and any Dimerizcr or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed Patent Rights.

xx1903 is for the treatment of GvHD as an orphan drug.

GvHD shall mean a clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patients organs and tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells.

Cell Transplantation Indication shall mean GvHD or any other acute or chronic adverse clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or in the case of a bone marrow, hematopoietic or stem cell product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product.

Licensed Products include  BPX-101 (formerly BP-GMAX-CDJ) , and, CaspaCIDe Donor Lymphocyte Infusion.

Field of Use
Licensed Field shall mean the treatment or prevention of the progression or occurrence in humans of any Primary Indication and/ or any Additional Indication, such as kidney cancer, or any noncancer indication, as the case may be.

Licensee is developing cell therapies to treat cancers and other chronic and life-threatening diseases.

IPSCIO Record ID: 367305

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patents and Licensed Technology to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Territory and in the Field of Use only.
License Property
Licensor owns one hundred percent interest in the Human Gene Therapy Research Institute located in Des Moines, Iowa.

Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.

The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
ATM Vector;
Dual adenoviral delivery of transgenes.

The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.

Field of Use
HyperAcute immunotherapies are designed to break tolerance and enable longer duration of anti-tumor effect.  HyperAcute immunotherapy technology has a wide range of anti-cancer applications including two additional product candidates, HyperAcute Lung and HyperAcute Melanoma, in active clinical development.  HyperAcute immunotherapy technology is designed to fight cancer by activating the human body's naturally protective and rapid immune response to the a-Gal carbohydrate.  HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which a-Gal is present by activating complement, an important component of the immune system that is capable of cell destruction. After destruction, we believe the resulting cellular fragments bound by anti-a-Gal antibodies are processed by the immune system to elicit an enhanced multi-faceted immune response to tumor-associated antigens common to both the immunotherapy and the patient's tumor cells.

IPSCIO Record ID: 279353

License Grant
Licensor and Licensee of Japan established a collaborative relationship on September 26, 1997 to conduct research and develop certain gene therapy products for the treatment of human cancer,  which Licensee shall have the right to commercialize in the Territory and Licensor shall have the right to commercialize outside the Territory.

With this new commercialization license, Licensor grants to the Licensee of Japan an exclusive, license under the Licensor Technology and Licensors interest in the Joint Technology, to make, have made  use, sell and otherwise commercialize Collaboration Products for all uses in the Field in the Territory.

License Property
Licensor has expertise in the field of gene therapy and is developing novel, proprietary materials and methods for use in the treatment of human cancer.

CD vector shall mean either a DART Vector or a GV11 Vector, in either case that incorporates the nucleic acid sequence for cytosme deaminase and does not incorporate any other nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit.

Gene Therapy shall mean the introduction of a nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit into a person for therapeutic purposes by in vivo introduction for incorporation into cells of such person, or by ex vivo introduction into cells for transfer into a person.

Field of Use
TheField shall mean Gene Therapy for the treatment of human cancer, Excluding any use of any DART Vector delivered by means of direct injection into a tumor.

IPSCIO Record ID: 308745

License Grant
Licensors (of Denmark and Germany) hereby grant to Liechtenstein Licensee the non-exclusive irrevocable royalty-bearing, licence, with the right to sublicense, under the Licensed Patent Rights to further develop, make, have made (including services under contract for Licensee or sub-licensee, by Contract Manufacturing Organizations, Contract Research Organisations, Consultants, Logistics Companies or others), obtain marketing approval, sell and offer for sale the Licensed Product or otherwise use the Licensed Patent Rights in the Territory within the Field of this Agreement.
License Property
6,776,985 – Encapsulated cells producing viral particles
6,540,995 – Encapsulated cells producing cytochrome P450
6,893,634 – Encapsulated cells producing cytochrome P450

Licensors are a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.

Field of Use
Field of this Agreement shall mean the development, manufacture, sale and/or distribution of Licensed Products or other use based on the Licensed Patent Rights and Clinical Data directed to encapsulated cells producing viral particles and encapsulated cells expressing biomolecules.

Cell encapsulation technology is for use in oncology and diabetes.

The Licensee is utilizing a cellulose-based live cell encapsulation technology, referred to as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

IPSCIO Record ID: 28224

License Grant
The UK University hereby grants to the Licensee
  (a)  an exclusive license in the Territory under the Licensed Technology to conduct research on, develop and commercialize the Licensed Technology, to manufacture, have manufactured, use and have used, market, sell, have sold, offer for sale, have offered for sale, import and export and have imported and exported the compositions, technology or inventions, and to practice (or practise) the processes or methods that are within or that constitute the Licensed Technology for use in the Field.
  (b)  the right to grant Sublicenses (with the right of such sublicensees to grant further sublicenses).
License Property
Licensor owns or has rights in certain technology regarding vectors and the capturing of genes.

Licensed Technology means Improvements, Inventions, Information and Know-How and Patents.
Patents means
  (a)  (i)  Patent number 5,767,336 granted in the United States of America entitled 'Gene Trap Vectors Comprising a Type II Transmembrane Domain', issued August 4,
  1998;
   (ii) Patent number 5,789,653 granted in the United States of America entitled 'Secretary Gene Trap', issued June 16, 1998;
   (iii)    Patent number 673,650 granted in Australia entitled 'Novel Vectors and Use Thereof for Capturing Target Genes', issued March 4, 1997

'Antisense Product' means a product which incorporates oligonucleotides that bind to either (a) mRNA to prevent the translation of mRNA, or protein production m vivo, or '(b) DNA to prevent the transcription of DNA into the mRNA copy of the gene in vivo; in each case, solely to the extent that such oligonucleotides (x) were directly developed from the practiceof any process or method claimed in the Patents or (y) contains a composition of matter claimed in the Patents, and (z) are covered by one or more Valid Claims.

Field of Use
'Field' means the use of vectors in biochemical, cellular and molecular biology research, development and commercialization relating to genes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.